Sanofi to expand its biggest global capacity center in India
STOCKHOLM, July 18, 2024 /PRNewswire/ -- Sobi® today announced the publication of full results from the Phase 3 XTEND-Kids study in The New England Journal of Medicine (NEJM) confirming the safety and efficacy profile of ALTUVOCT® (efanesoctocog alfa), in children younger than 12 years old with severe haemophilia A. The study demonstrated that fixed-dose once-weekly prophylaxis with ALTUVOCT, a new class of high-sustained factor VIII therapy, provided highly effective bleed protection in children.
NEJM publishes ALTUVIIIO XTEND-Kids phase 3 data supporting its potential to transform the treatment landscape for children with severe hemophilia A ALTUVIIIO provides high-sustained...
$21 million public-private project led by the Foundation for the National Institutes of Health (FNIH) will see government agencies, nonprofits and industry giants hunt for biomarkers that distinguish Parkinson’s diseases from similar conditions.
Sanofi is looking to bulk up its workforce at its global capacity center in Hyderabad, India, with a multi-year investment totaling 400 million euros ($437 million), according to reports. nnThe investment will stretch through the end of the decade, with the first chunk of 100 million euros ($109 million) coming by next year, The Hindu reports.
BRUSSELS, July 17 (Reuters) - Europe's second-top court on Wednesday said the European Commission did not give the public sufficient access to the purchase agreements for COVID-19 vaccines during the pandemic, upholding a challenge brought by EU lawmakers against the EU executive's handling of the deals.
US Senator Sanders optimistic Novo Nordisk can be pressured to cut Wegovy, Ozempic prices
The dog days of summer might be in full swing, but for flu vaccine makers, its a busy time prepping for this fall's influenza season.
Genzyme `s Biologic Fabrazyme (Agalsidase Beta) Receives Suppl Approvals in US
Genzyme `s Biologic Cerezyme (Imiglucerase ) Receives Suppl Approvals in US